Atossa Plans CVR Tied To Potential Rare Pediatric Disease Voucher

Atossa Therapeutics' board approved issuing one contingent value right (CVR) for each common share, giving shareholders rights to potential proceeds tied to the company's first qualifying Rare Pediatric Disease Priority Review Voucher. The action could create additional contingent value for ATOS holders, though the ultimate payout depends on achievement of the qualifying regulatory milestone and any resulting voucher proceeds.